Paul Taylor is a Senior Editor at eRepublic, where he covers a range of topics including competitive sports, healthcare technology, and pharmaceuticals. He has a keen interest in both individual and team sports, blending his expertise in sports business with insights into medicine and healthcare. Paul has been featured in numerous publications, including The Independent, Forbes, and The New York Times.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Paul Taylor's coverage mainly focuses on sports, particularly football (soccer), baseball, and ice hockey, with specific attention to the Nottingham Forest, Toronto Blue Jays, and Edmonton Oilers. Given this focus, he would likely be interested in receiving pitches related to these teams or general trends within these sports.
As Paul's articles often cite data and cover specific events related to the teams mentioned above, he may be open to pitches from individuals who can provide unique insights backed by relevant statistics or insider information about players' performances and team strategies.
Since his coverage is spread across different sports and teams without a specified geographic focus, consider tailoring your pitches based on the specific topics covered in his articles.
This information evolves through artificial intelligence and human feedback. Improve this profile .
What are we even doing here? By Paul Taylor |
It's time for Cal to get going. By Paul Taylor |
Saturday played into the narrative of this M's season. By Paul Taylor |
By: Nick, Paul Taylor
Chai Discovery has continued its whirlwind emergence, closing its third financing round in less than a year to bring its total funding haul above $600 million.
"Randy being Randy" can sometimes be good. By Paul Taylor |
Attovia Therapeutics has filed for an IPO to secure funding for assets including a potential challenger to Sanofi and Regeneron's Dupixent and Galderma's Nemluvio.
By: Nick, Paul Taylor
An inspection of a facility making Elevar's rivoceranib uncovered deficiencies, leading the FDA to reject a combination therapy that includes the drug. The rebuff is the third strike for the partners after the agency issued manufacturing-related denials for the other drug in the combo.
Johnson & Johnson has stopped development of an eye disease gene therapy after reviewing data from one of its key readouts for 2026.
A poster boy for the Mariners' issues in 2026. By Paul Taylor |
By: Paul Taylor
Even Hal Baleigh would have struggled. By Paul Taylor |
